Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 1:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: HIV Pre-Exposure Prophylaxis Clear all
Recruiting Not applicable Interventional Accepts healthy volunteers

HIV Pre-Exposure Prophylaxis (PrEP) Linkage With Immediate Medications in the Emergency Department Study

NCT07462611
View directory record Official record
Conditions
HIV Pre-exposure Prophylaxis, PrEP
Interventions
PrEP Uptake with Rapid Start, Pre-Exposure Prophylaxis (PrEP) Persistence
Behavioral
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Sep 25, 2026, 1:26 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

MyPrEP Plus: Development and Pilot Testing of Novel Preexposure Prophylaxis Decision Support Tools for Transgender Women

NCT07146139
View directory record Official record
Conditions
HIV Pre-exposure Prophylaxis, HIV Prevention and Care, Mobile Health Technology (mHealth), Adherence, Doxycycline STI PEP
Interventions
MyPrEP Plus Package, Standard of Care (SOC)
Device · Behavioral
Lead sponsor
Public Health Foundation Enterprises, Inc.
Other
Eligibility
18 Years and older · Male only
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 27, 2025 · Synced Sep 25, 2026, 1:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug-Drug Interaction Study of MK 8527 With a Combined Oral Contraceptive (LNG/EE)

NCT06783192
View directory record Official record
Conditions
Human Immunodeficiency Virus (HIV), HIV Pre-Exposure Prophylaxis
Interventions
MK-8527, LNG/EE
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 70 Years · Female only
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 19, 2025 · Synced Sep 25, 2026, 1:26 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Combination Primary Care and Prevention Services for Women Who Inject Drugs and Exchange Sex in Seattle, Washington

NCT06187064
View directory record Official record
Conditions
Opioid Use Disorder, HIV Infections, Chlamydia, Gonorrhea, Syphilis, Trichomonas
Interventions
Mobile Van Clinic
Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Sep 25, 2026, 1:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Exploring HIV Entry Blockade as a Pre-exposure Prophylaxis Strategy in Women

NCT01749566
View directory record Official record
Conditions
HIV
Interventions
maraviroc
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older · Female only
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 8, 2015 · Synced Sep 25, 2026, 1:26 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

PrEPTECH Phase 2 Study of a PrEP Telehealth Intervention

NCT04902820
View directory record Official record
Conditions
Pre-Exposure Prophylaxis, HIV, Telemedicine
Interventions
PrEPTECH website, Online PrEP resource list
Other
Lead sponsor
ETR Associates
Other
Eligibility
15 Years to 27 Years · Male only
Enrollment
229 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Scotts Valley, California
Source: ClinicalTrials.gov public record
Updated Sep 10, 2023 · Synced Sep 25, 2026, 1:26 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Mobile-Based Application "MyChoices"

NCT03179319
View directory record Official record
Conditions
HIV, Sexually Transmitted Diseases, Pre-exposure Prophylaxis, Risk Reduction
Interventions
MyChoices
Behavioral
Lead sponsor
Fenway Community Health
Other
Eligibility
15 Years to 24 Years · Male only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
2
States / cities
Boston, Massachusetts • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Dec 15, 2020 · Synced Sep 25, 2026, 1:26 AM EDT
Active, not recruiting No phase listed Observational

Infectious Disease (ID) Testing OUtreach in Carceral Hubs

NCT06679751
View directory record Official record
Conditions
HIV Infections, Opioid Use Disorder
Interventions
Not listed
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 25, 2026, 1:26 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Transgender Youth and PrEP: PK, Safety, Uptake & Adherence - Intervention Development

NCT04077138
View directory record Official record
Conditions
HIV/AIDS, Gender, Behavior and Behavior Mechanisms
Interventions
Not listed
Lead sponsor
Hektoen Institute for Medical Research
Other
Eligibility
15 Years to 24 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
3
States / cities
Denver, Colorado • Chicago, Illinois • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 31, 2024 · Synced Sep 25, 2026, 1:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Rectal Insert TAF/EVG Pre-Exposure Prophylaxis (RITE PrEP) Study

NCT06274398
View directory record Official record
Conditions
Safety Issues
Interventions
TAF/EVG rectal insert, Matching placebo rectal insert
Drug
Lead sponsor
Eastern Virginia Medical School
Other
Eligibility
18 Years to 59 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 24, 2025 · Synced Sep 25, 2026, 1:26 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

An Open Label Demonstration Project and Phase II Safety Study of Pre-Exposure Prophylaxis Use Among 15 to 17 Year Old Young Men Who Have Sex With Men (YMSM)

NCT01769456
View directory record Official record
Conditions
HIV Infection
Interventions
PCC, Emtricitabine/tenofovir (FTC/TDF (Truvada®))
Behavioral · Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
15 Years to 17 Years · Male only
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
6
States / cities
Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2018 · Synced Sep 25, 2026, 1:26 AM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Implementation and Deliver of Lenacapavir for PrEP in a Community Pharmacy Setting

NCT07210125
View directory record Official record
Conditions
HIV
Interventions
Lenacapavir long-acting, Standard of Care (SOC)
Drug · Other
Lead sponsor
Kelley-Ross & Associates, Inc.
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Sep 25, 2026, 1:26 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Electronic Pre-exposure Prophylaxis (PrEP) Initiation and Maintenance Home Care System

NCT03729570
View directory record Official record
Conditions
Pre-exposure Prophylaxis
Interventions
ePrEP
Other
Lead sponsor
Emory University
Other
Eligibility
18 Years to 29 Years · Male only
Enrollment
217 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
4
States / cities
Birmingham, Alabama • Atlanta, Georgia • Jackson, Mississippi + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2024 · Synced Sep 25, 2026, 1:26 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Stick2PrEP Cisgender Women and Trans Individuals

NCT05165745
View directory record Official record
Conditions
HIV Prevention, Pre-exposure Prophylaxis
Interventions
Individualized Feedback
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 1, 2025 · Synced Sep 25, 2026, 1:26 AM EDT
Not yet recruiting Not applicable Interventional

PrEPwise Pilot Among Black Women in Eastern Virginia

NCT07398482
View directory record Official record
Conditions
HIV Infections, Sexually Transmitted Infection
Interventions
PrEPwise, Usual care
Behavioral · Other
Lead sponsor
Boston University
Other
Eligibility
18 Years and older · Female only
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Sep 25, 2026, 1:26 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Leveraging Electronic Health Record Data in a Risk Prediction Model to Increase HIV PrEP Intake in Primary Care

NCT05991869
View directory record Official record
Conditions
Pre-Exposure Prophylaxis
Interventions
Point-of-care decision support intervention
Behavioral
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Sep 25, 2026, 1:26 AM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) in Prevention of HIV in Cisgender Women in the United States (HPTN 102)

NCT06101329
View directory record Official record
Conditions
Pre-Exposure Prophylaxis of HIV Infection
Interventions
Lenacapavir Tablet, Lenacapavir Injection, Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF)
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older · Female only
Enrollment
253 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
11
States / cities
Birmingham, Alabama • San Diego, California • Washington D.C., District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 25, 2026, 1:26 AM EDT
Not yet recruiting No phase listed Observational

Are Louisiana Pharmacists PrEPared? Implementing Training and an Active PrEP (Pre-Exposure Prophylaxis) Prescribing Surveillance Program

NCT06530225
View directory record Official record
Conditions
HIV Prevention
Interventions
Education and Mentoring for Prescribing Pharmacists
Other
Lead sponsor
Xavier University of Louisiana.
Other
Eligibility
24 Years to 99 Years
Enrollment
75 participants
Timeline
2027 – 2030
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 25, 2026, 1:26 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety, Tolerability and Acceptability of Long-Acting Cabotegravir (CAB LA) for the Prevention of HIV Among Adolescent Males

NCT04692077
View directory record Official record
Conditions
HIV Infections
Interventions
Cabotegravir (CAB) tablet, CAB LA, Tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) tablet
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Up to 17 Years · Male only
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
4
States / cities
Aurora, Colorado • Chicago, Illinois • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated May 19, 2025 · Synced Sep 25, 2026, 1:26 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Phase II Safety and Acceptability of an Investigational Injectable Product, TMC278LA, for Pre-Exposure Prophylaxis

NCT02165202
View directory record Official record
Conditions
Human Immunodeficiency Virus (HIV)
Interventions
Rilpivirine, Placebo
Drug
Lead sponsor
PATH
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
136 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
2
States / cities
Newark, New Jersey • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 26, 2018 · Synced Sep 25, 2026, 1:26 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Evaluation of Doxycycline Post-exposure Prophylaxis to Reduce Sexually Transmitted Infections in PrEP Users and HIV-infected Men Who Have Sex With Men

NCT03980223
View directory record Official record
Conditions
Gonorrhea, Chlamydia, Syphilis
Interventions
Doxycycline Hyclate Delayed-Release 200 mg
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Male only
Enrollment
641 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
3
States / cities
San Francisco, California • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 11, 2024 · Synced Sep 25, 2026, 1:26 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Renal, Endocrine, and Bone Changes in Response to FTC/TDF in Uninfected Young Men Who Have Sex With Men (YMSM).

NCT01769469
View directory record Official record
Conditions
HIV Infection
Interventions
FTC/TDF (Truvada®)
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
15 Years to 22 Years · Male only
Enrollment
101 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
12
States / cities
Los Angeles, California • Aurora, Colorado • Miami, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2019 · Synced Sep 25, 2026, 1:26 AM EDT
Active, not recruiting Phase 4 Interventional

Tshireletso: Safety, Efficacy and Feasibility of Cabotegravir-LA PrEP in a Breastfeeding Population in Botswana

NCT05986084
View directory record Official record
Conditions
Pre-Exposure Prophylaxis (PrEP), Breast Feeding
Interventions
Cabotegravir Injection [Apretude]
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 25, 2026, 1:26 AM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers Results available

Study of Lenacapavir for HIV Pre-Exposure Prophylaxis in People Who Are at Risk for HIV Infection

NCT04925752
View directory record Official record
Conditions
Pre-Exposure Prophylaxis of HIV Infection
Interventions
Oral Lenacapavir (LEN), F/TDF, Sub-cutaneous (SC) Lenacapavir (LEN), Placebo SC LEN, PTM F/TDF, PTM Oral LEN, F/TAF (for US participants only)
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
16 Years and older
Enrollment
3,292 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2028
U.S. locations
60
States / cities
Birmingham, Alabama • Loma Linda, California • Los Angeles, California + 43 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Sep 25, 2026, 1:26 AM EDT